Technology & Software Global On demand · 24-48h

Global Drug Safety and Pharmacovigilance (PV) Software Market Strategic Research Report

Name: Global Drug Safety and Pharmacovigilance (PV) Software Market Strategic Research Report
Brand: Market Research Reports, Inc.
Price: 3500 USD
Availability: PreOrder

Global Drug Safety and Pharmacovigilance (PV) Software Marke…

$3,500 USD

Strategic Research Report

Global Drug Safety and Pharmacovigilance (PV) Software Market

$2752025

5.4%CAGR

2032Forecast

Market Research Reports · Global

Market Research Reports Intelligence Series

By Type: On-Premises, Cloud-Based

By Application: Pharma and Biotech Companies, Contract Research Organizations (CROs), Business Process Outsourcing (BPO) Firms, Other

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Oracle, Veeva Systems, ArisGlobal, IQVIA, EXTEDO, RxLogix, Ennov, Uppsala Monitoring Centre, Medidata, Clarivate, AB Cube, Cloudbyz, Cognizant Technology, Taimei Technology, eMedyun, Bioknow, Singedi Health

Region: Global

Formats: PDF, Excel, Word & PowerPoint

Base year: 2025 · forecast to 2032

Length: 125 pages

Market size 2025

$275

Million USD

Forecast CAGR

5.4%

2025-2032

Forecast 2032

$397.4

Projected

Regiões

Asia Pacific · Latin America · MEA · Europe · North America

Visão geral

Scope of the Report

The global Drug Safety and Pharmacovigilance (PV) Software market size is predicted to grow from US$ 275 million in 2025 to US$ 398 million in 2032; it is expected to grow at a CAGR of 5.4% from 2026 to 2032.

Drug Safety and Pharmacovigilance (PV) Software is an automated, information-based tool used by pharmaceutical companies, healthcare institutions, and regulatory authorities to monitor, assess, and prevent adverse drug reactions (ADRs) and safety risks throughout the entire drug lifecycle. It ensures drug compliance, aims to protect public health, improve patient safety, and meet the legal obligations of marketing authorization holders (MAHs).

As global drug regulatory agencies (such as the FDA, EMA, and NMPA) continue to tighten post-marketing regulatory requirements, the traditional manual review-based Individual Case Safety Report (ICSR) processing model can no longer cope with the explosive growth of massive amounts of data. Current leading opinions emphasize that by 2026, the core competitiveness of the market will focus on the full-stack integration capability of AI, that is, whether software can automate the entire process from scanning original documents and automatically sorting cases to providing scientific writing suggestions through large language models and natural language processing. This transformation makes pharmacovigilance software no longer just a database tool, but an indispensable "risk warning center" in pharmaceutical companies' R&D decision-making.

This report presents a comprehensive overview of the global Drug Safety and Pharmacovigilance (PV) Software market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

On-Premises
Cloud-Based

Segment by Data Range

Pre-market
Post-market

Segment by Functional Modules

Security Database
Signal Detection
Compliance Report
Other

Segment by Application

Pharma and Biotech Companies
Contract Research Organizations (CROs)
Business Process Outsourcing (BPO) Firms
Other

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Drug Safety and Pharmacovigilance (PV) Software market:

Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
Distributors, channel partners and end users in Pharma and Biotech Companies, Contract Research Organizations (CROs), Business Process Outsourcing (BPO) Firms evaluating demand and sourcing options
Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Drug Safety and Pharmacovigilance (PV) Software Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports

Market size CAGR 5.4%

Regional growth momentum

Market share by segment

Key metrics

Base value

$275

2025

Forecast

$397.4

2032

CAGR

5.4%

2025–2032

Regiões

global

Key companies

OracleVeeva SystemsArisGlobalIQVIAEXTEDORxLogixEnnovUppsala Monitoring Centre

Segments covered in this report

By Type

On-PremisesCloud-Based

By Application

Pharma and Biotech CompaniesContract Research Organizations (CROs)Business Process Outsourcing (BPO) FirmsOther

Click a chapter to expand

01Executive Summary

02Industry Overview & Forecast

2.1.1 Market Definition and Scope
2.1.2 Market Size and Growth Forecast
2.1.3 Volume Analysis
2.1.4 Segment Outlook by Type
2.1.5 Segment Outlook by Application
2.1.6 Regional Outlook
2.1.7 Structural Developments Shaping the Forecast
2.1.8 Forecast Risks and Sensitivities

03Market Segmentation by Type

3.1 Market Segmentation by Type
3.1.1 Market by Type Overview
3.1.2 On-Premises
3.1.3 Cloud-Based
3.1.4 Volume Analysis

04Market Segmentation by Application

4.1 Market Segmentation by Application
4.1.1 Market by Application Overview
4.1.2 Pharma and Biotech Companies
4.1.3 Contract Research Organizations (CROs)
4.1.4 Business Process Outsourcing (BPO) Firms
4.1.5 Other
4.1.6 Volume Analysis

05Regional Market Forecast

Asia Pacific
North America
Europe
Middle East & Africa
Latin America

06Country-Level Market Forecast

6.1 Asia Pacific
6.1.1 China
6.1.2 Japan
6.1.3 Korea
6.1.4 Southeast Asia
6.1.5 India
6.1.6 Australia
6.1.7 Rest of Asia Pacific
6.2 North America
6.2.1 United States
6.2.2 Canada
6.2.3 Mexico
6.2.4 Rest of North America
6.3 Europe
6.3.1 Germany
6.3.2 France
6.3.3 UK
6.3.4 Italy
6.3.5 Russia
6.3.6 Rest of Europe
6.4 Middle East & Africa
6.4.1 Egypt
6.4.2 South Africa
6.4.3 Israel
6.4.4 Turkey
6.4.5 GCC Countries
6.4.6 Rest of Middle East & Africa
6.5 Latin America
6.5.1 Brazil
6.5.2 Rest of Latin America

07Growth Drivers & Inhibitors

7.1 Growth Drivers & Inhibitors
7.1.1 Section Overview
7.1.2 Growth Drivers
7.1.3 Growth Inhibitors
7.1.4 Driver and Inhibitor Impact Assessment
7.1.5 Analyst Perspective

08Key Company Profiles

8.1 Oracle
8.1.1 Company Overview
8.1.2 Key Products & Segments
8.1.3 Financial Performance (2023–2025)
8.1.4 Business Strategy
8.1.5 SWOT Analysis
8.1.6 Strategic Implications (2026–2032)
8.2 Veeva Systems
8.2.1 Company Overview
8.2.2 Key Products & Segments
8.2.3 Financial Performance (2023–2025)
8.2.4 Business Strategy
8.2.5 SWOT Analysis
8.2.6 Strategic Implications (2026–2032)
8.3 ArisGlobal
8.3.1 Company Overview
8.3.2 Key Products & Segments
8.3.3 Financial Performance (2023–2025)
8.3.4 Business Strategy
8.3.5 SWOT Analysis
8.3.6 Strategic Implications (2026–2032)
8.4 IQVIA
8.4.1 Company Overview
8.4.2 Key Products & Segments
8.4.3 Financial Performance (2023–2025)
8.4.4 Business Strategy
8.4.5 SWOT Analysis
8.4.6 Strategic Implications (2026–2032)
8.5 EXTEDO
8.5.1 Company Overview
8.5.2 Key Products & Segments
8.5.3 Financial Performance (2023–2025)
8.5.4 Business Strategy
8.5.5 SWOT Analysis
8.5.6 Strategic Implications (2026–2032)
8.6 RxLogix
8.6.1 Company Overview
8.6.2 Key Products & Segments
8.6.3 Financial Performance (2023–2025)
8.6.4 Business Strategy
8.6.5 SWOT Analysis
8.6.6 Strategic Implications (2026–2032)
8.7 Ennov
8.7.1 Company Overview
8.7.2 Key Products & Segments
8.7.3 Financial Performance (2023–2025)
8.7.4 Business Strategy
8.7.5 SWOT Analysis
8.7.6 Strategic Implications (2026–2032)
8.8 Uppsala Monitoring Centre
8.8.1 Company Overview
8.8.2 Key Products & Segments
8.8.3 Financial Performance (2023–2025)
8.8.4 Business Strategy
8.8.5 SWOT Analysis
8.8.6 Strategic Implications (2026–2032)
8.9 Medidata
8.9.1 Company Overview
8.9.2 Key Products & Segments
8.9.3 Financial Performance (2023–2025)
8.9.4 Business Strategy
8.9.5 SWOT Analysis
8.9.6 Strategic Implications (2026–2032)
8.10 Clarivate
8.10.1 Company Overview
8.10.2 Key Products & Segments
8.10.3 Financial Performance (2023–2025)
8.10.4 Business Strategy
8.10.5 SWOT Analysis
8.10.6 Strategic Implications (2026–2032)
8.11 AB Cube
8.11.1 Company Overview
8.11.2 Key Products & Segments
8.11.3 Financial Performance (2023–2025)
8.11.4 Business Strategy
8.11.5 SWOT Analysis
8.11.6 Strategic Implications (2026–2032)
8.12 Cloudbyz
8.12.1 Company Overview
8.12.2 Key Products & Segments
8.12.3 Financial Performance (2023–2025)
8.12.4 Business Strategy
8.12.5 SWOT Analysis
8.12.6 Strategic Implications (2026–2032)
8.13 Cognizant Technology
8.13.1 Company Overview
8.13.2 Key Products & Segments
8.13.3 Financial Performance (2023–2025)
8.13.4 Business Strategy
8.13.5 SWOT Analysis
8.13.6 Strategic Implications (2026–2032)
8.14 Taimei Technology
8.14.1 Company Overview
8.14.2 Key Products & Segments
8.14.3 Financial Performance (2023–2025)
8.14.4 Business Strategy
8.14.5 SWOT Analysis
8.14.6 Strategic Implications (2026–2032)
8.15 eMedyun
8.15.1 Company Overview
8.15.2 Key Products & Segments
8.15.3 Financial Performance (2023–2025)
8.15.4 Business Strategy
8.15.5 SWOT Analysis
8.15.6 Strategic Implications (2026–2032)
8.16 Bioknow
8.16.1 Company Overview
8.16.2 Key Products & Segments
8.16.3 Financial Performance (2023–2025)
8.16.4 Business Strategy
8.16.5 SWOT Analysis
8.16.6 Strategic Implications (2026–2032)
8.17 Singedi Health
8.17.1 Company Overview
8.17.2 Key Products & Segments
8.17.3 Financial Performance (2023–2025)
8.17.4 Business Strategy
8.17.5 SWOT Analysis
8.17.6 Strategic Implications (2026–2032)

09Competitive Landscape

9.1 Competitive Landscape Overview
9.2 Competitive Intensity Assessment
9.3 Key Player Strategies & Positioning
9.4 Competitive Dynamics & Strategic Outlook
9.4.1 Emerging Competitive Threats
9.4.2 Consolidation vs. Fragmentation Outlook
9.4.3 Competitive Response Matrix
9.4.4 Strategic Recommendations, 2026–2032

10Porter's Five Forces Analysis

10.1 Threat of New Entrants
10.2 Bargaining Power of Buyers
10.3 Bargaining Power of Suppliers
10.4 Threat of Substitutes
10.5 Competitive Rivalry

11PESTLE Analysis

11.1 Political
11.2 Economic
11.3 Social and Demographic
11.4 Technological
11.5 Legal and Regulatory
11.6 Environmental
11.7 Strategic Implications of the PESTLE Assessment

12SWOT Analysis

13Future Trends & Outlook

13.1 Future Trends & Outlook
13.1.1 Trend Summary and Commercial Maturity Assessment
13.1.2 Technology and Innovation Trends
13.1.3 Long-Term Market Outlook
13.1.4 Investment & M&A Activity Outlook
13.1.5 Overall Outlook Assessment

Frequently asked questions

What is the current global Drug Safety and Pharmacovigilance (PV) Software market size?

The global Drug Safety and Pharmacovigilance (PV) Software market is estimated at US$ 275 million in 2025 (base year) and is projected to reach US$ 398 million by 2032.

What growth rate is expected for the Drug Safety and Pharmacovigilance (PV) Software market through 2032?

The market is expected to grow at a CAGR of 5.4% from 2026 to 2032, expanding from US$ 275 million in 2025 to US$ 398 million in 2032, roughly 1.4 times its base-year value.

How is Drug Safety and Pharmacovigilance (PV) Software defined?

How is the Drug Safety and Pharmacovigilance (PV) Software market segmented by type?

By type, the market is segmented into On-Premises and Cloud-Based.

What are the key applications of Drug Safety and Pharmacovigilance (PV) Software?

Key applications covered include Pharma and Biotech Companies, Contract Research Organizations (CROs), Business Process Outsourcing (BPO) Firms and Other.

Which companies are profiled in the Drug Safety and Pharmacovigilance (PV) Software market report?

Key players profiled include Oracle, Veeva Systems, ArisGlobal, IQVIA, EXTEDO, RxLogix, Ennov and Uppsala Monitoring Centre, among 17 companies covered in total.

What geographies does the Drug Safety and Pharmacovigilance (PV) Software market analysis include?

The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.

Who should buy the Drug Safety and Pharmacovigilance (PV) Software market report?

The report is intended for manufacturers and solution providers, distributors and end users in Pharma and Biotech Companies, Contract Research Organizations (CROs) and Business Process Outsourcing (BPO) Firms, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Drug Safety and Pharmacovigilance (PV) Software market.

What license options are available for this report?

The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.